20.500.12556/DiRROS-13699 T2-high asthma, classified by sputum mRNA expression of IL4, IL5, and IL13, is characterized by eosinophilia and severe phenotype Asthma is a common chronic disease, with different underlying inflammatory mechanisms. Identification of asthma endotypes, which reflect a variable response to different treatments, is important for more precise asthma management. T2 asthma is characterized by airway inflammation driven by T2 cytokines including interleukins IL-4, IL-5, and IL-13. This study aimed to determine whether induced sputum samples can be used for gene expression profiling of T2-high asthma classified by IL4, IL5, and IL13 expression. Induced sputum samples were obtained from 44 subjects, among them 36 asthmatic patients and eight controls, and mRNA expression levels of IL4, IL5, and IL13 were quantified by RT-qPCR. Overall, gene expression levels of IL4, IL5, and IL13 were significantly increased in asthmatic patients' samples compared to controls and there was a high positive correlation between expressions of all three genes. T2 gene mean was calculated by combining the expression levels of all three genes (IL4, IL5, and IL13) and according to T2 gene mean expression in controls, we set a T2-high/T2-low cutoff value. Twenty-four (67%) asthmatic patients had T2-high endotype and those patients had significantly higher eosinophil blood and sputum counts. Furthermore, T2-high endotype was characterized as a more severe, difficult-to-treat asthma, and often uncontrolled despite the use of inhaled and/or oral corticosteroids. Therefore, the majority of those patients (15 [63%] of 24) needed adjunct biological therapy to control their asthma symptoms/exacerbations. In conclusion, we found that interleukins IL4, IL5, and IL13 transcripts could be effectively detected in sputum from asthmatic patients. Implementation of T2 gene mean can be used as sputum molecular biomarker to categorize patients into T2-high endotype, characterized by eosinophilia and severe, difficult-to-treat asthma, and often with a need for biological treatment. asthma gene expression interleukin-4 interleukin-5 interleukin-13 severe asthma endotype IL-4 IL-5 IL-13 biologic treatment astma gensko izražanje interlevkin-4 interlevkin-5 interlevkin-13 težka astma endotip IL-4 IL-5 IL-13 biološko zdravljenje true false true MDPI Angleški jezik Ni določen © 2021 by the authors. Neznano 2021-02-02 13:43:02 2021-02-02 13:43:04 2022-08-19 03:36:09 0000-00-00 00:00:00 2021 0 Švica 0 Nasl. z nasl. zaslona; Soavtorji: Tomaž Krumpestar, Sabina Škrgat, Izidor Kern, Peter Korošec; Opis vira z dne 29. 1. 2021; Št. članka: 92; str. 1-10 iss. 2 Vol. 1 Feb. 2020 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 616-097 2075-1729 10.3390/life11020092 49321987 519982617 RAZ_Rijavec_Matija_i2021.pdf RAZ_Rijavec_Matija_i2021.pdf 1 E6C630E451F9E0DB5B885A8A25B633A4 7694f4f76f279dea7da684dedee2f322296e9c7c8b0a0bb2df86f91bbf0be82c 844636be-17b6-11ed-b6b8-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=17146 https://www.mdpi.com/2075-1729/11/2/92/pdf 1 https://dirros.openscience.si/Dokument.php?lang=slv&id=16729 Univerzitetna klinika za pljučne bolezni in alergijo Golnik 0 0 0